PortfoliosLab logoPortfoliosLab logo
SBIO vs. NLR
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

SBIO vs. NLR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALPS Medical Breakthroughs ETF (SBIO) and VanEck Uranium and Nuclear ETF (NLR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SBIO achieves a -1.72% return, which is significantly lower than NLR's -0.79% return. Over the past 10 years, SBIO has underperformed NLR with an annualized return of 8.36%, while NLR has yielded a comparatively higher 12.72% annualized return.


SBIO

1D
-0.36%
1M
-9.33%
YTD
-1.72%
6M
-2.48%
1Y
59.38%
3Y*
16.69%
5Y*
1.33%
10Y*
8.36%

NLR

1D
0.91%
1M
-12.54%
YTD
-0.79%
6M
-6.08%
1Y
26.72%
3Y*
31.16%
5Y*
20.16%
10Y*
12.72%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO vs. NLR - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SBIO
ALPS Medical Breakthroughs ETF
-1.72%55.07%3.81%8.68%-28.08%-17.55%21.17%50.30%-11.81%45.67%
NLR
VanEck Uranium and Nuclear ETF
-0.79%56.50%14.26%36.67%2.29%13.63%3.49%0.20%4.94%8.25%

Correlation

The correlation between SBIO and NLR is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.30

Correlation (3Y)
Calculated over the trailing 3-year period

0.33

Correlation (5Y)
Calculated over the trailing 5-year period

0.39

Correlation (10Y)
Calculated over the trailing 10-year period

0.33

Correlation (All Time)
Calculated using the full available price history since Jan 2, 2015

0.31

SBIO vs. NLR - Sectors Allocation Comparison


Sectors
SBIO
NLR

Healthcare

100.0%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

46.0%

Industrials

-

15.1%

Real Estate

-

-

Technology

-

1.5%

Utilities

-

37.4%

Financial Services

-0.0%

-

Healthcare

SBIO
100.0%
NLR

-

Basic Materials

SBIO

-

NLR

-

Communication Services

SBIO

-

NLR

-

Consumer Cyclical

SBIO

-

NLR

-

Consumer Defensive

SBIO

-

NLR

-

Energy

SBIO

-

NLR
46.0%

Industrials

SBIO

-

NLR
15.1%

Real Estate

SBIO

-

NLR

-

Technology

SBIO

-

NLR
1.5%

Utilities

SBIO

-

NLR
37.4%

Financial Services

SBIO
-0.0%
NLR

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SBIO vs. NLR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO
SBIO Risk / Return Rank: 7373
Overall Rank
SBIO Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
SBIO Sortino Ratio Rank: 7070
Sortino Ratio Rank
SBIO Omega Ratio Rank: 6060
Omega Ratio Rank
SBIO Calmar Ratio Rank: 8888
Calmar Ratio Rank
SBIO Martin Ratio Rank: 7878
Martin Ratio Rank

NLR
NLR Risk / Return Rank: 2222
Overall Rank
NLR Sharpe Ratio Rank: 2121
Sharpe Ratio Rank
NLR Sortino Ratio Rank: 2323
Sortino Ratio Rank
NLR Omega Ratio Rank: 2121
Omega Ratio Rank
NLR Calmar Ratio Rank: 2424
Calmar Ratio Rank
NLR Martin Ratio Rank: 1919
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO vs. NLR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and VanEck Uranium and Nuclear ETF (NLR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SBIONLRDifference
Sharpe ratioReturn per unit of total volatility

+1.39

Sortino ratioReturn per unit of downside risk

+1.71

Omega ratioGain probability vs. loss probability

1.33

1.13

+0.20

Calmar ratioReturn relative to maximum drawdown

4.72

1.04

+3.67

Martin ratioReturn relative to average drawdown

13.54

2.08

+11.46

SBIO vs. NLR - Sharpe Ratio Comparison

The current SBIO Sharpe Ratio is 2.02, which is higher than the NLR Sharpe Ratio of 0.63. The chart below compares the historical Sharpe Ratios of SBIO and NLR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SBIONLRDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

2.02

0.63

+1.39

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.04

0.69

-0.65

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.25

0.53

-0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

0.21

0.16

+0.05

Drawdowns

SBIO vs. NLR - Drawdown Comparison

The maximum SBIO drawdown since its inception was -63.06%, roughly equal to the maximum NLR drawdown of -65.05%. Use the drawdown chart below to compare losses from any high point for SBIO and NLR.


Loading charts...

Drawdown Indicators


SBIONLRDifference

Max Drawdown

Largest peak-to-trough decline

-63.06%

-65.05%

+1.99%

Max Drawdown (1Y)

Largest decline over 1 year

-12.66%

-25.80%

+13.14%

Max Drawdown (3Y)

Largest decline over 3 years

-42.44%

-30.48%

-11.96%

Max Drawdown (5Y)

Largest decline over 5 years

-53.10%

-30.48%

-22.62%

Max Drawdown (10Y)

Largest decline over 10 years

-63.06%

-34.35%

-28.71%

Current Drawdown

Current decline from peak

-17.90%

-25.03%

+7.13%

Average Drawdown

Average peak-to-trough decline

-28.43%

-35.71%

+7.28%

Ulcer Index

Depth and duration of drawdowns from previous peaks

4.40%

12.87%

-8.47%

Volatility

SBIO vs. NLR - Volatility Comparison

The current volatility for ALPS Medical Breakthroughs ETF (SBIO) is 9.87%, while VanEck Uranium and Nuclear ETF (NLR) has a volatility of 13.36%. This indicates that SBIO experiences smaller price fluctuations and is considered to be less risky than NLR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SBIONLRDifference

Volatility (1M)

Calculated over the trailing 1-month period

9.87%

13.36%

-3.49%

Volatility (6M)

Calculated over the trailing 6-month period

22.68%

33.24%

-10.56%

Volatility (1Y)

Calculated over the trailing 1-year period

29.62%

42.96%

-13.34%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.56%

29.43%

+4.13%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

33.18%

24.14%

+9.04%

SBIO vs. NLR - Expense Ratio Comparison

SBIO has a 0.50% expense ratio, which is lower than NLR's 0.56% expense ratio.


Dividends

SBIO vs. NLR - Dividend Comparison

SBIO has not paid dividends to shareholders, while NLR's dividend yield for the trailing twelve months is around 2.57%.


PositionTTM20252024202320222021202020192018201720162015
NLR
VanEck Uranium and Nuclear ETF
2.57%2.55%0.76%4.54%2.02%1.99%2.23%2.21%3.91%4.86%3.62%3.30%
SBIO
ALPS Medical Breakthroughs ETF
0.00%0.00%3.55%0.22%0.00%0.00%0.00%0.04%2.79%1.77%0.00%0.00%

Frequently Asked Questions


SBIO and NLR have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NLR has higher volatility (13.36%) compared to SBIO (9.87%). In terms of maximum drawdown, SBIO dropped -63.06% vs NLR's -65.05%.

On 10-year performance, NLR leads with 12.72% vs 8.36% for SBIO. On fees, SBIO is cheaper at 0.50% per year. On volatility, SBIO has been the lower-risk option at 9.87%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 10-year period, NLR has performed better with a 12.72% return vs 8.36%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

SBIO is cheaper with a 0.50% expense ratio, compared with 0.56% for NLR.

NLR has the higher dividend yield at 2.57%, compared with 0.00% for SBIO.

SBIO is categorized as Health & Biotech Equities, while NLR is Alternative Energy Equities. SBIO tracks S-Network Medical Breakthroughs Index, while NLR tracks MVIS Global Uranium & Nuclear Energy Index. They also come from different issuers: SS&C and VanEck. Their fees differ too: 0.50% for SBIO and 0.56% for NLR.

SBIO currently has the higher Sharpe Ratio (2.02 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SBIO and NLR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer